166 related articles for article (PubMed ID: 36828828)
1. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
Noori S; Wijnands C; Langerhorst P; Bonifay V; Stingl C; Touzeau C; Corre J; Perrot A; Moreau P; Caillon H; Luider TM; Dejoie T; Jacobs JFM; van Duijn MM
Blood Cancer J; 2023 Feb; 13(1):30. PubMed ID: 36828828
[No Abstract] [Full Text] [Related]
2. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
[TBL] [Abstract][Full Text] [Related]
3. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease.
O'Brien A; O'Halloran F; Mykytiv V
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):e34-e40. PubMed ID: 34470720
[TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
Thoren KL
Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M; Badbaran A; Fehse B; Bacher U; Zander AR; Kröger NM
Bone Marrow Transplant; 2008 May; 41(10):913-6. PubMed ID: 18264143
[No Abstract] [Full Text] [Related]
8. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.
de Tute RM; Jack AS; Child JA; Morgan GJ; Owen RG; Rawstron AC
Leukemia; 2007 Sep; 21(9):2046-9. PubMed ID: 17657223
[No Abstract] [Full Text] [Related]
9. Go with the flow for monitoring response in myeloma with minimal residual disease.
Mason KD; Juneja S
Leuk Lymphoma; 2008 Feb; 49(2):177-8. PubMed ID: 18231901
[No Abstract] [Full Text] [Related]
10. Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
Roshal M
Semin Hematol; 2018 Jan; 55(1):4-12. PubMed ID: 29759152
[TBL] [Abstract][Full Text] [Related]
11. An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
Austin M; O'Connor S; Morilla R; Pawlyn C; Kaiser MF; Boyd KD
Int J Lab Hematol; 2020 Apr; 42(2):e65-e67. PubMed ID: 31539199
[No Abstract] [Full Text] [Related]
12. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.
Soh KT; Tario JD; Wallace PK
Clin Lab Med; 2017 Dec; 37(4):821-853. PubMed ID: 29128071
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
[No Abstract] [Full Text] [Related]
14. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
Flanders A; Stetler-Stevenson M; Landgren O
Blood; 2013 Aug; 122(6):1088-9. PubMed ID: 23929839
[No Abstract] [Full Text] [Related]
15. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
[TBL] [Abstract][Full Text] [Related]
16. Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.
Iwaki K; Fujiwara T; Ito T; Suzuki C; Sasaki K; Ono K; Saito K; Fukuhara N; Onishi Y; Yokoyama H; Fujimaki S; Tanaka T; Tamura H; Fujiwara M; Harigae H
Tohoku J Exp Med; 2019 Sep; 249(1):19-28. PubMed ID: 31511451
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
19. Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy.
Clark CA; Mosse CA; Chen H; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Kassim AA; Savani BN; Sengsayadeth S; Jagasia M; Cornell RF
Bone Marrow Transplant; 2018 Dec; 53(12):1589-1592. PubMed ID: 29915217
[No Abstract] [Full Text] [Related]
20. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
